Half Yearly Report

RNS Number : 4520P
ValiRx PLC
19 August 2014
 



 

 

For release at 07:00 on 19 August 2014

 

ValiRx Plc

("ValiRx" or "the Company")

 

Half Year Results

 

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces its interim results for the half year ended 30 June 2014.

 

HIGHLIGHTS

Operational Highlights

·      Submission of clinical trial application ("CTA") and regulatory authorisation to progress VAL201 in human patient studies. This was accepted in August 2014; patient recruitment will commence on obtaining a favourable opinion on the authorised procedure from the Ethics Committee; 

 

·      Expansion of product portfolio with ValiRx entering into a risk-sharing joint venture agreement with Tangent Reprofiling Limited ("Tangent Reprofiling") to progress the drug VAL401 through its remaining pre-clinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications;

 

·      Confirmation of safety of VAL401 from toxicological studies.   We can now plan future detailed regulatory toxicology and pharmacokinetic studies with greater confidence in securing a positive outcome for clinical studies; and

 

·      Securing of patent protection in the major markets. ValiRx now has granted patent protection for the NAV3 gene biomarker in Japan, Europe and Australia, and pending in the US and other territories, alongside granted and pending patents for its therapeutic technologies across Europe, the US, Canada and Australia.

 

Financial Highlights

·      Sale of 510,811 shares in VolitionRx for US$601,578;

 

·      Expenditure on Research and Development was down 43% to £0.56m as a result of forward ordering of the VAL201 compound in 2013 to build robust stability and sterility data ahead of filing the "CTA" application;

 

·      Administration expenses were £0.64m (2013: £0.68m);

 

·      Loss after taxation was £1.34m (2013: £1.49m) or 0.05p per ordinary share (2013: 0.09p); 

 

·      Total comprehensive loss for the period of £1.75m (2013: £1.63m);

 

·      Cash and cash equivalents as at 30 June 2014 of £0.76m (2013: £1.17m)

 

Oliver de Giorgio-Miller, Non-Exec Chairman of ValiRx, commented:

"We have made substantial progress during this period and are very pleased to see both VAL201 now making its way down the regulatory pathway and our portfolio of drug candidates enhanced and enlargedWith the Company's costs under control and with its lead therapeutics and other assets moving forward, as planned, the Company remains adequately funded to proceed with its current plans. I look forward to updating shareholders on further progress throughout the year."

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 3008 4416

Dr Satu Vainikka

www.valirx.com



Cairn Financial Advisers LLP (Nominated Adviser)

Tel: +44 (0) 20 7148 7900

Liam Murray / Avi Robinson




Daniel Stewart & Company Plc (Broker)

Tel: +44 (0) 20 7776 6550

David Hart

 


Peckwater PR

Tel: +44 (0) 7879 458 364

Tarquin Edwards

tarquin.edwards@peckwaterpr.co.uk

 

CHAIRMAN'S STATEMENT FOR THE HALF YEAR ENDED 30 AUGUST 2014

We are making strong progress this year in delivering our key priorities, which include taking our leading anti-cancer therapeutic VAL201 into clinical trials, expanding our product portfolio and progressing the biomarker side of the business.

This progress particularly applies to VAL201, for which the Company, with the support of its clinical trial project team, has successfully obtained Medicines and Healthcare Products Regulatory Agency ("MHRA") approval to enter the drug in a Phase l/II escalation study in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours. We anticipate this study will commence before the end of this calendar year.

We have also expanded our portfolio of drug candidates through a joint venture arrangement with Tangent Reprofiling to further develop VAL401, a novel combination cancer drug with an already established safety profile.  The joint venture has been formed to complete VAL401's remaining pre-clinical development and the Board believe this work will act as the springboard required to take VAL401 to Phase II trials for the treatment of lung cancer and other oncological indications.

We now have three therapeutics in our portfolio, VAL201, VAL101 and VAL401, each having multiple cancer indications.  Alongside these, in the case of our GeneICE / VAL101 compounds, we have the potential to spawn a series of treatments for neurological and inflammatory diseases.  

The growth in both strength and depth of our business has been replicated at our subsidiary company, ValiFinn, which has developed and validated a range of companion diagnostics or genetic biomarkers to pair with the compounds VAL201 and VAL401. 

In sum, we have made substantial progress during this period and are very pleased to see both VAL201 now making its way down the regulatory pathway and our portfolio of drug candidates enhanced and enlarged.  With the Company's costs under control and with its lead therapeutics and other assets moving forward, as planned, the Company remains adequately funded to proceed with its current plans.  I look forward to updating shareholders on further progress throughout the year.

Oliver de Giorgio-Miller

Non-Executive Chairman

19 August 2014



  Six months ended


  Six months ended


Year ended


Note

30 June


30 June


31 December



2014


2013


2013



(unaudited)


(unaudited)


(audited)



£


£


£















Revenue


              59,574


            103,999


            124,868








Cost of sales


-


(25,179)


(51,618)

Gross profit


              59,574


              78,820


              73,250








Research and development


(558,202)


(972,219)


(1,622,383)

Administrative expenses


(640,400)


(683,593)


(1,361,954)















Operating loss


(1,139,028)


(1,576,992)


(2,911,087)








Finance income


                7,214


                4,319


                5,552

Fair value loss on derivative financial assets


(361,218)


                       


                       

Finance costs


                       
-


(26)


(180)








Loss before income taxation


(1,493,032)


(1,572,699)


(2,905,715)








Income tax credit

3

            150,000


              75,000


            308,477








Loss on ordinary activities after taxation


(1,343,032)


(1,497,699)


(2,597,238)








Non-controlling interests


              32,044


                       
-


                      
-



(1,310,988)


(1,497,699)


(2,597,238)

Other comprehensive income







Loss on sale of/ change in fair value of available-for-sale assets


(437,493)


(134,400)


(105,020)








Loss for the period and total comprehensive income attributable to owners of the parent


(1,748,481)


(1,632,099)


(2,702,258)








Loss per share - basic and diluted

4

(0.05)p


(0.09)p


(0.15)p




Statement of changes in shareholders' equity



Share capital


Share premium


Retained earnings


Merger reserve


Share option reserve


Reverse acquisition reserve


 Non-controlling interest


 Total



£


£


£


£


£


£




£

Unaudited

















Balance at 1 January 2014


    6,359,357


    5,925,231


(10,367,941)


       637,500


         73,852


       602,413


                   -  


    3,230,412

Loss for the period


                   -  


                   -  


(1,310,988)


                   


                   -  


                   -  


(32,044)


(1,343,032)

On acquisition of subsidiary


                   -  


                   -  


-


                   


                   -  


                   -  


                 30


                 30

Loss on sale of available-for-sale assets


                   -  


                   -  


(437,492)


                   


                   -  


                   -  


                   -  


(437,492)

Issue of shares


       922,448


    2,069,702


                   -  


                   


                   -  


                   -  




    2,992,150

Movement in period


                   -  


(390,201)


                   -  


                   
-


                   -  


                   -  




(390,201)

Share based payment


                   -  


                   -  


                   -  


                   
-


    1,658,800


                   -  


                   -  


    1,658,800

Balance at 30 June 2014


    7,281,805


    7,604,732


(12,116,421)


       637,500


    1,732,652


       602,413


(32,014)


    4,106,409


















Unaudited

















Balance at 1 January 2013


    6,051,607


    5,337,152


(7,665,683)


       637,500


         73,852


       602,413


                   -  


    5,036,841

Loss for the period


                   -  


                   -  


(1,497,699)


                   


                   -  


                   -  


                   -  


(1,497,699)

Change in fair value of available-for-sale assets


                   -  


                   -  


(134,400)


                   


                   -  


                   -  


                   -  


(134,400)

Issue of shares


                   -  


                   -  


                   -  


                   


                   -  


                   -  


                   -  


                   -  

Share based payment


                   -  


                   -  


                   -  


                   


         21,002


                   -  


                   -  


         21,002

Balance at 30 June 2013


    6,051,607


    5,337,152


(9,297,782)


       637,500


         94,854


       602,413


                   -  


    3,425,744


















Audited

















Balance at 1 January 2013


    6,051,607


    5,337,152


(7,665,683)


637,500


         73,852


       602,413


                   -  


    5,036,841

Loss for the year


                   -  


                   -  


(2,597,238)


                   


                   -  


                   -  


                   -  


(2,597,238)

Change in fair value of available-for-sale assets


                   -  


                   -  


(105,020)


                   


                   -  


                   -  


                   -  


-      105,020

Issue of shares


       307,750


       692,437


                   -  


                   


                   -  


                   -  


                   -  


    1,000,187

Movement in period


                   -  


(104,358)


                   -  


                   


                   -  


                   -  


                   -  


(104,358)

Share based payment


                   -  


                   -  


                   -  


                   


                   -  


                   -  


                   -  


                   -  

Balance at 31 December 2013


    6,359,357


    5,925,231


(10,367,941)


       637,500


         73,852


       602,413


                   -  


    3,230,412


Consolidated statement of financial position



As at 30 June


31 December



2014


2013


2013



(unaudited)


(unaudited)


(audited)



£


£


£

ASSETS







Non current assets







Intangible assets


        2,074,111


        1,850,735


        1,882,762

Property, plant and equipment


                    657


                1,126


                    685

Derivative financial assets


              63,440


                       -  


                       -  

Financial assets: available-for-sale investments


                       


            738,943


            768,323










        2,138,208


        2,590,804


        2,651,770








Current assets







Inventories


                6,255


                3,789


                4,078

Trade and other receivables


            568,670


            477,928


            490,395

Derivative financial assets


            761,282


                       -  


                       -  

Cash and cash equivalents


            757,589


        1,172,191


            960,267



        2,093,796


        1,653,908


        1,454,740








LIABILITIES







Current liabilities







Trade and other payables


(125,595)


(818,968)


(876,098)








NET CURRENT ASSETS


        1,968,201


            834,940


            578,642








NET ASSETS


        4,106,409


        3,425,744


        3,230,412








SHAREHOLDERS' EQUITY







Share capital


        7,281,805


        6,051,607


        6,359,357

Share premium account


        7,604,732


        5,337,152


        5,925,231

Merger reserve


            637,500


            637,500


            637,500

Reverse acquisition reserve


            602,413


            602,413


            602,413

Share option reserve


        128,394


              94,854


              73,852

Retained earnings


(12,116,421)


(9,297,782)


(10,367,941)










        4,138,423


        3,425,744


        3,230,412

Non-controlling interest


(32,014)


                       -  


                       -  








Total equity


        4,106,409


        3,425,744


        3,230,412









Year ended



Six months ended 30 June


31 December



2014


2013


2013



(unaudited)


(unaudited)


(audited)



£


£


£

Operating activities







Operating loss


(1,139,028)


(1,576,992)


(2,911,087)

Depreciation of property plant and equipment


                      -  


               3,277


             5,623

Amortisation of intangible assets


            26,998


            22,490


            55,537

Increase in inventories


(2,177)


(1,062)


(1,351)

Decrease/(increase) in receivables


            71,725


(49,073)


             7,045

(Decrease)/increase in payables within one year


(718,353)


         557,333


         614,463

Other non-cash movements


             4,593


                627


(2,782)

Share option charge


    54,542


           21,002


                    








Cash outflows from operating activities


(1,701,700)


(1,022,398)


(2,232,552)








Taxation


                     


                  - 


         164,892








Investing activities







Interest received


              7,214


              4,319


              5,552

Interest paid


                       -  


(26)


(180)

Payments to acquire intangible assets


(162,881)


(70,447)


(132,135)

Payments to acquire property plant and equipment


                       -  


(40)


(1,922)

Receipts from sale of available- for- sale investments


          330,830


                    
-


                       -  








Net cash inflow/(outflow) from investing activities


            175,163


(66,194)


(128,685)








Financing activities







Issue of ordinary share capital


        2,900,000


                    
-


        1,000,187

Cost of share issue


(390,201)


                    
-


(104,358)

Payments to acquire derivative financial assets


(1,500,000)


                    
-


                      -  

Receipts from issue of derivative financial assets


          314,060


                    
-


                      -  








Net cash generated from financing activities


        1,323,859


                    
-


           895,829








Net decrease in cash and cash equivalents


(202,678)


(1,088,592)


(1,300,516)








Cash and cash equivalents at start of period


          960,267


       2,260,783


        2,260,783








Cash and cash equivalents at end of period


           757,589


       1,172,191


          960,267



Notes to the interim financial statements

1              General information

ValiRx Plc is a company incorporated in the United Kingdom, which is listed on the AIM Market of the London Stock Exchange Plc. The address of its registered office is 24 Greville Street, London EC1N 8SS.

2              Financial information

The interim consolidated financial information for the six months ended 30 June 2014 has not been audited or reviewed and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The Group's statutory accounts for the year ended 31 December 2013 have been delivered to the Registrar of Companies. The report of the independent auditors on those financial statements was unqualified and did not contain a statement under Sections 498 (2) or (3) of the Companies Act 2006.

 

The interim financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union, IFRIC interpretations and the Companies Act 2006 applicable to companies reporting under IFRS and under the historical cost convention. The accounting policies applied in preparing the interim financial information are consistent with those set out in the statutory accounts of the Company for the year ended 31 December 2013.

 

The interim consolidated financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the group operates.

 

 

3              Taxation

 



  Six months ended


  Six months ended


Year ended



30 June


30 June


31 December



2014


2013


2013



(unaudited)


(unaudited)


(audited)



£


£


£

United Kingdom corporation tax at 20%







  Current period - R & D Tax credit


(150,000)


(75,000)


(309,541)








Foreign corporation tax


-


-


127

 

Income tax credit


(150,000)


(75,000)


(165,956)

 

4              Loss per ordinary shares

The loss and number of shares used in the calculation of loss per share are as follows:



  Six months ended


  Six months ended


Year ended



30 June


30 June


31 December



2014


2013


2013



(unaudited)


(unaudited)


(audited)

Basic:







Loss for the financial period


(1,748,481)


(1,497,699)


(2,597,238)

Weighted average number of shares


 2,941,382,514


 1,711,184,409


 1,733,106,298

Loss per share


(0.05)p


(0.09)p


(0.15)p

 

5              Dividends

The directors do not propose to declare a dividend in respect of the period.

 

6              Share capital



30 June 2014


30 June 2013



Number


 £


Number


 £



(unaudited)


(unaudited)


(unaudited)


(unaudited)

Allotted, called up and fully paid









Ordinary shares of 0.1p each


  2,941,382,514


        2,941,383


  1,711,184,409


        1,711,184

Deferred shares of 5.0p each


     58,378,365


        2,918,918


     58,378,365


        2,918,918

Deferred shares of 0.9p each


   157,945,030


        1,421,505


   157,945,030


        1,421,505





         7,281,805




         6,051,607












31 December 2013







Number


 £





Allotted, called up and fully paid


(unaudited)


(unaudited)





Ordinary shares of 0.1p each


2,018,934,009


         2,018,934





Deferred shares of 5.0p each


     58,378,365


         2,918,918





Deferred shares of 0.9p each


   157,945,030


         1,421,505









          6,359,357





 

The deferred shares effectively have no rights or value.

7              Copies of interim results

Copies of the interim results can be obtained from the website www.valirx.com. From this site you may access our financial reports and presentations, recent press releases and details about the company and its operations.

 

 

 

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.

The Company operates through the following divisional companies:

1. ValiFinn is the biomarkers and diagnostic development division

2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR GGUAURUPCGRR

Companies

Valirx (VAL)
UK 100

Latest directors dealings